Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of RO7269162 in at-risk and prodromal Alzheimer's disease
2023-506183-13-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing RO7269162 with Placebo (2 arms). Primary endpoints: Safety and tolerability: adverse events, Safety parameters: vital signs, ECG, C-SSRS, labs and 1 more. Planned start Mar 2024; status: authorised.
02
Drugs
nivegacetor
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-506183-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506183-13-00.